When we last sat down with Jobs at TechCrunch Disrupt nearly three years ago, his firm Yosemite was brand new and biotech was still reeling from its post-pandemic crash. Now, the venture outfit has a team of 17; a cluster of blockbuster drugs are all losing patent protection in roughly the same window, creating all kinds of new opportunities; and AI has gone from a curiosity to, in Jobs's words, a huge part of what Yosemite does. "I didn't expect Yosemite to be moving this fast," he said.
Last weekend’s brutal NYC heat wave had me craving a frozen drink almost every afternoon. Normally, that would mean sweating through a walk to 7-Eleven for a slurpee. This time, though, I stayed home and put the new Ninja Slushi Twist to the test. Ninja’s latest slushie machine builds on the popularity of the original […]